NovoCure Beheer

Beheer criteriumcontroles 3/4

De CEO NovoCure is Asaf Danziger, benoemd in Jan2002, heeft een ambtstermijn van 22.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.52M, bestaande uit 49.7% salaris en 50.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde R$ 1.51M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.6 jaar en 7 jaar.

Belangrijke informatie

Asaf Danziger

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris	49.7%
Dienstverband CEO	22.8yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Asaf Danziger's beloning veranderd ten opzichte van NovoCure's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$150m
Jun 30 2024	n/a	n/a	-US$169m
Mar 31 2024	n/a	n/a	-US$193m
Dec 31 2023	US$2m	US$756k	-US$207m
Sep 30 2023	n/a	n/a	-US$197m
Jun 30 2023	n/a	n/a	-US$174m
Mar 31 2023	n/a	n/a	-US$141m
Dec 31 2022	US$2m	US$831k	-US$93m
Sep 30 2022	n/a	n/a	-US$82m
Jun 30 2022	n/a	n/a	-US$68m
Mar 31 2022	n/a	n/a	-US$59m
Dec 31 2021	US$1m	US$876k	-US$58m
Sep 30 2021	n/a	n/a	-US$27m
Jun 30 2021	n/a	n/a	-US$5m
Mar 31 2021	n/a	n/a	US$12m
Dec 31 2020	US$9m	US$782k	US$20m
Sep 30 2020	n/a	n/a	US$19m
Jun 30 2020	n/a	n/a	US$12m
Mar 31 2020	n/a	n/a	US$9m
Dec 31 2019	US$7m	US$702k	-US$7m
Sep 30 2019	n/a	n/a	-US$27m
Jun 30 2019	n/a	n/a	-US$41m
Mar 31 2019	n/a	n/a	-US$55m
Dec 31 2018	US$5m	US$693k	-US$64m
Sep 30 2018	n/a	n/a	-US$59m
Jun 30 2018	n/a	n/a	-US$59m
Mar 31 2018	n/a	n/a	-US$64m
Dec 31 2017	US$4m	US$698k	-US$62m

Compensatie versus markt: De totale vergoeding ($USD 1.52M ) Asaf } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de BR markt ($USD 687.82K ).

Compensatie versus inkomsten: De vergoeding van Asaf is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Asaf Danziger (58 yo)

22.8yrs

Tenure

US$1,521,026

Compensatie

Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Doyle	Executive Chairman	20.8yrs	US$1.43m	0.51% R$ 54.7m
Asaf Danziger	CEO & Director	22.8yrs	US$1.52m	0.014% R$ 1.5m
Ashley Cordova	Chief Financial Officer	4.2yrs	US$6.32m	0.085% R$ 9.1m
Barak Arye	General Counsel	2.6yrs	US$4.86m	0.019% R$ 2.1m
Frank Leonard	Executive VP & President of Novocure Oncology	4.2yrs	US$5.04m	0.055% R$ 5.9m
Yoram Palti	Founder & CTO	24.8yrs	US$282.51k	geen gegevens
Mukund Paravasthu	Chief Operating Officer	less than a year	geen gegevens	0.0032% R$ 343.5k
Ingrid Goldberg	VP of Investor Relations	no data	geen gegevens	geen gegevens
Michael Puri	Chief Human Resources Officer	1.2yrs	geen gegevens	0.012% R$ 1.3m
Uri Weinberg	Chief Innovation Officer	1.8yrs	geen gegevens	0.057% R$ 6.1m
Piet Hinoul	Senior VP	no data	geen gegevens	geen gegevens
Nicolas Leupin	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van N2VC34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
William Doyle	Executive Chairman	20.8yrs	US$1.43m	0.51% R$ 54.7m
Asaf Danziger	CEO & Director	12.8yrs	US$1.52m	0.014% R$ 1.5m
Jeryl Hilleman	Independent Director	6.3yrs	US$446.09k	0.0023% R$ 251.2k
David Hung	Independent Director	6.5yrs	US$426.09k	0.0084% R$ 907.1k
Timothy Scannell	Independent Director	3.8yrs	US$448.53k	0.0036% R$ 389.7k
Kinyip Leung	Independent Director	13.1yrs	US$435.53k	0.073% R$ 7.9m
William Vernon	Lead Independent Director	18.8yrs	US$475.53k	0.15% R$ 16.0m
Martin Madden	Independent Director	7.5yrs	US$446.09k	0.014% R$ 1.6m
Kristin Stafford	Independent Director	1.7yrs	US$696.94k	0% R$ 0
Allyson Ocean	Independent Director	1.8yrs	US$697.26k	0% R$ 0

7.0yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van N2VC34 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

NovoCure Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

NovoCure Limited Announces CFO Appointment

Novocure Announces CEO Changes, Effective January 1, 2025

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited Announces Executive Changes

Recent updates

Novocure FDA Approves Novocure’S Innovative HFE Transducer Arrays for Use with Optune Gio® for Glioblastoma

NovoCure Limited Announces CFO Appointment

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

NovoCure Limited to Report Q3, 2024 Results on Oct 30, 2024

Novocure Announces CEO Changes, Effective January 1, 2025

Novocure Announces CEO Changes, Effective January 1, 2025

NovoCure Limited(NasdaqGS:NVCR) dropped from Russell 1000 Dynamic Index

NovoCure Limited to Report Q2, 2024 Results on Jul 25, 2024

Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial

Novocure Releases Topline Efficacy and Safety Data from the TIGER Study Investigating the Use of Tumor Treating Fields Therapy in the Treatment of Patients with Newly Diagnosed Glioblastoma in Germany

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

Novocure Announces Resignation of Todd Longsworth as General Counsel

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd